University of Miami Sylvester Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 88
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: UA61268B303EN
Leaflet:

Download PDF Leaflet

University of Miami Sylvester Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “University of Miami Sylvester Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope
  • Review of therapeutics under development by University of Miami Sylvester Comprehensive Cancer Center.
  • Overview of products under development across various therapy areas.
  • Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of University of Miami Sylvester Comprehensive Cancer Center with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of University of Miami Sylvester Comprehensive Cancer Center’s therapeutic products in the last quarter.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify new drug targets and therapeutic classes in University of Miami Sylvester Comprehensive Cancer Center’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
  • Evaluate University of Miami Sylvester Comprehensive Cancer Center’s position with total access to a detailed information on its therapeutic products development.
  • Assess the growth potential of University of Miami Sylvester Comprehensive Cancer Center in its therapy areas of focus.
  • Exploit collaboration and partnership opportunities with University of Miami Sylvester Comprehensive Cancer Center.
  • Avoid Intellectual Property Rights related issues.
University of Miami Sylvester Comprehensive Cancer Center Snapshot
University of Miami Sylvester Comprehensive Cancer Center Overview
Key Information
Key Facts
University of Miami Sylvester Comprehensive Cancer Center – Research and Development Overview
Key Therapeutic Areas
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Products Glance
University of Miami Sylvester Comprehensive Cancer Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University of Miami Sylvester Comprehensive Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
University of Miami Sylvester Comprehensive Cancer Center – Drug Profiles
Fluconazole + Radiation therapy
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane
  Product Description
  Mechanism of Action
  R&D Progress
Abraxane + Bevacizumab + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
amifostine trihydrate + cisplatin + fluorouracil + paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
amifostine trihydrate + cisplatin + fluorouracil + paclitaxel + radiation therapy
  Product Description
  Mechanism of Action
  R&D Progress
Arsenic Trioxide + Ascorbic Acid
  Product Description
  Mechanism of Action
  R&D Progress
Bevacizumab + Floxuridine + Irinotecan hydrochloride + Leucovorin calcium
  Product Description
  Mechanism of Action
  R&D Progress
Bevacizumab + Gemcitabine hydrochloride + Abraxane
  Product Description
  Mechanism of Action
  R&D Progress
bevacizumab + gemcitabine hydrochloride + paclitaxel albumin-stabilized nanoparticle formulation
  Product Description
  Mechanism of Action
  R&D Progress
Capecitabine + Docetaxel
  Product Description
  Mechanism of Action
  R&D Progress
carboplatin + docetaxel + irinotecan hydrochloride + radiation therapy
  Product Description
  Mechanism of Action
  R&D Progress
carboplatin + sorafenib tosylate
  Product Description
  Mechanism of Action
  R&D Progress
cisplatin + doxorubicin hydrochloride
  Product Description
  Mechanism of Action
  R&D Progress
cisplatin + sorafenib tosylate
  Product Description
  Mechanism of Action
  R&D Progress
cyclophosphamide + docetaxel + doxorubicin hydrochloride + glutathione disulfide NOV-002
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Carboplatin
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Floxuridine + Leucovorin + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + rituximab + cyclophosphamide + cytarabine + doxorubicin hydrochloride + etoposide + ifosfamide + leucovorin calcium + mesna + methotrexate + vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
filgrastim + rituximab + cyclophosphamide + cytarabine + doxorubicin hydrochloride + etoposide + ifosfamide + leucovorin calcium + mesna + methotrexate + vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Oxaliplatin + Sorafenib
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine Hydrochloride + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
Oxaliplatin + Capecitabine
  Product Description
  Mechanism of Action
  R&D Progress
pegylated arginine deiminase
  Product Description
  Mechanism of Action
  R&D Progress
porfimer sodium
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Leucovorin calcium + Methotrexate + Thalidomide + Vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
rituximab + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine sulfate
  Product Description
  Mechanism of Action
  R&D Progress
rituximab + gemcitabine hydrochloride + vinorelbine ditartrate
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab + Methotrexate + Doxorubicin + Cyclophosphamide + Leucovorin + Vincristine + Ifosfamide + Etoposide + Cytarabine + Thalidomide
  Product Description
  Mechanism of Action
  R&D Progress
rituximab + Yttrium Y 90 Ibritumomab Tiuxetan
  Product Description
  Mechanism of Action
  R&D Progress
Vidaza + Docetaxel + Prednisone
  Product Description
  Mechanism of Action
  R&D Progress
Ad100-gp96Ig-HLA A1
  Product Description
  Mechanism of Action
  R&D Progress
Arsenic trioxide + Bortezomib + Melphalan + Autologous hematopoietic stem cell transplantation
  Product Description
  Mechanism of Action
  R&D Progress
Arsenic trioxide + Fluorouracil + Leucovorin calcium
  Product Description
  Mechanism of Action
  R&D Progress
celecoxib
  Product Description
  Mechanism of Action
  R&D Progress
cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Cytochlor + Tetrahydrouridine + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Ixabepilone + Sunitinib
  Product Description
  Mechanism of Action
  R&D Progress
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Analysis
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Products by Therapeutic Class
University of Miami Sylvester Comprehensive Cancer Center Pipeline Products By Target
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Products by Route of Administration
University of Miami Sylvester Comprehensive Cancer Center – Pipeline Products by Molecule Type
University of Miami Sylvester Comprehensive Cancer Center – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

University of Miami Sylvester Comprehensive Cancer Center – Pipeline by Therapy Area and Indication, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline by Stage of Development, 2010
University of Miami Sylvester Comprehensive Cancer Center – Monotherapy Products in Pipeline, 2010
University of Miami Sylvester Comprehensive Cancer Center – Combination Treatment Modalities in Pipeline, 2010
University of Miami Sylvester Comprehensive Cancer Center – Phase III, 2010
University of Miami Sylvester Comprehensive Cancer Center - Phase II, 2010
University of Miami Sylvester Comprehensive Cancer Center - Phase I, 2010
University of Miami Sylvester Comprehensive Cancer Center - Pipeline By Therapeutic Class, 2010
University of Miami Sylvester Comprehensive Cancer Center - Pipeline By Target, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline By Route of Administration, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline By Molecule Type, 2010
University of Miami Sylvester Comprehensive Cancer Center, Other Locations 86

LIST OF FIGURES

University of Miami Sylvester Comprehensive Cancer Center – Pipeline by Therapy Area and Indication, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline by Stage of Development, 2010
University of Miami Sylvester Comprehensive Cancer Center – Monotherapy Products in Pipeline, 2010
University of Miami Sylvester Comprehensive Cancer Center – Combination Treatment Modalities in Pipeline, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline By Therapeutic Class, 2010
University of Miami Sylvester Comprehensive Cancer Center - Pipeline By Target, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline By Route of Administration, 2010
University of Miami Sylvester Comprehensive Cancer Center – Pipeline By Molecule Type, 2010 85

Ask Your Question

University of Miami Sylvester Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: